Literature DB >> 17784885

Prostatic involvement by urothelial carcinoma of the bladder: clinicopathological features and outcome after radical cystectomy.

Rajinikanth Ayyathurai1, Pablo Gomez, Tony Luongo, Mark S Soloway, Murugesan Manoharan.   

Abstract

OBJECTIVES: To review the long-term outcome of prostatic involvement in patients with bladder cancer (BC) treated with radical cystectomy (RC), as urothelial carcinoma (UC) involving the prostate occurs in such patients, and prostatic invasion by UC is by transmural invasion (contiguous), or when UC develops from the epithelium of the prostatic urethra (not contiguous). PATIENTS AND METHODS: Between 1992 and 2006, 351 men had RC for BC by one surgeon at our centre; they were stratified into those with contiguous or non-contiguous disease, based on prostatic stromal involvement. Relevant clinical and pathological data were collected and the survival analysed.
RESULTS: In all, 24% (78/320) of the patients who had RC had prostatic involvement; 29 (9%) and 49 (15%) had contiguous and non-contiguous involvement, respectively. In the non-contiguous group, there was stromal and non-stromal UC involvement in 18 (37%) and 31 (63%), respectively. The overall 5-year survival of contiguous, non-contiguous and no prostatic involvement was 6%, 57% and 66% (P < 0.001). The 5-year overall survival of stromal and non-stromal UC was 26% and 74% (P = 0.008). There was no statistical difference in survival between contiguous and non-contiguous stromal involvement (P = 0.58).
CONCLUSIONS: Prostatic UC with no stromal involvement did not alter the survival predicted by the primary bladder stage. Stromal involvement of the prostate has a poor prognosis regardless of the mode of invasion.

Entities:  

Mesh:

Year:  2007        PMID: 17784885     DOI: 10.1111/j.1464-410X.2007.07171.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  6 in total

1.  Clinical outcomes of urothelial carcinoma of the prostate detected in radical cystectomy specimens.

Authors:  Koji Ichihara; Naoya Masumori; Hiroshi Kitamura; Tadashi Hasegawa; Taiji Tsukamoto
Journal:  Int J Clin Oncol       Date:  2012-12-19       Impact factor: 3.402

2.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

3.  Full analysis of the prostatic urethra at the time of radical cystoprostatectomy for bladder cancer: impact on final disease stage.

Authors:  Justine Varinot; Philippe Camparo; Morgan Roupret; Marc Olivier Bitker; Fréderique Capron; Olivier Cussenot; J Alfred Witjes; Eva Compérat
Journal:  Virchows Arch       Date:  2009-10-20       Impact factor: 4.064

4.  Usefulness of transurethral biopsy for staging the prostatic urethra before radical cystectomy.

Authors:  Friedrich Carl von Rundstedt; Seth P Lerner; Guilherme Godoy; Gilad Amiel; Thomas M Wheeler; Luan D Truong; Steven S Shen
Journal:  J Urol       Date:  2014-08-12       Impact factor: 7.450

5.  Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy.

Authors:  Marco Moschini; Francesco Soria; Martin Susani; Stephan Korn; Alberto Briganti; Morgan Roupret; Christian Seitz; Killian Gust; Andrea Haitel; Francesco Montorsi; Gregory Wirth; Brian D Robinson; Pierre I Karakiewicz; Mehmet Özsoy; Michael Rink; Shahrokh F Shariat
Journal:  Bladder Cancer       Date:  2017-07-27

6.  Double cocktail immunostains with high molecular weight cytokeratin and GATA-3: useful stain to discriminate in situ involvement of prostatic ducts or acini from stromal invasion by urothelial carcinoma in the prostate.

Authors:  Junghye Lee; Youngeun Yoo; Sanghui Park; Min-Sun Cho; Sun Hee Sung; Jae Y Ro
Journal:  J Pathol Transl Med       Date:  2020-02-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.